BPH Treatment Devices To Be Reimbursed By HCFA At Approximately $1,875

EDAP expects that the lower cost of its Prostatron microwave-based system for treating benign prostatic hyperplasia will make the product more attractive than competing devices now that therapy has been assigned an ambulatory payment classification (APC) code with a set reimbursement level.